Johnson & Johnson Q3 Sales Rise, But Stock Drops on MedTech Miss
What happened
Johnson & Johnson reported Q3 sales of $25.4 billion, a 6% increase, and adjusted EPS of $2.59. The company raised its full-year sales forecast to approximately $101.2 billion. However, the stock fell 5.96% following the report, which was attributed to a soft MedTech quarter and deal dilution.
From aol.com
Why it matters
The market compared Johnson & Johnson's 21x forward P/E ratio against Eli Lilly and Company's 24x P/E and Pfizer's 10x P/E. This valuation comparison highlights differences among major pharmaceutical competitors. Analysts noted that strong pharmaceutical brands offset the soft MedTech quarter for Johnson & Johnson.
Financial results and stock performance are being compared among Johnson & Johnson, Eli Lilly and Company, and Pfizer.
From aol.com
Who's involved
- Johnson & JohnsonReported Q3 earnings and raised full-year sales guidance.
- Eli Lilly and CompanyUsed as a benchmark for P/E ratio comparison against Johnson & Johnson.
- PfizerUsed as a benchmark for P/E ratio comparison against Johnson & Johnson.
- Helios Investment PartnersMay have investment holdings in MedTech affected by the stock drop.
- James FrithMay have investment holdings in MedTech affected by the stock drop.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Helios Investment PartnersSpeculative
Helios Investment Partners might see investment holdings in MedTech negatively affected by Johnson & Johnson's stock drop and segment miss.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.Keep exploring
The entities involved
-
Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
-
Eli Lilly and Company
American pharmaceutical company
-
Pfizer
American multinational pharmaceutical and biotechnology corporation